Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Barbara Ann Karmanos Cancer Institute
With
United States Department of Defense
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histological diagnosis of prostate cancer
Evidence of metastatic disease by radiologic criteria
Bone scan within 4 weeks of starting therapy
Creatinine within 2 weeks of registration, calculated creatinine clearance \> 60ml/min.
Minimum life expectancy of 6 months
Willingness to have pre-therapy PET scans performed within 2 weeks after registration and post therapy PET scan performed within 1 week after dose of Zometa (a total of 3 PET scans required)
Calculated creatinine clearance \> 50ml/min.
No prior Zoledronate therapy
Patients must have disease progression despite testosterone suppression (level\<50ng/ml); progression can be by rising PSA ( at least 2 values at least 2 weeks apart) or by new lesions on scans or progression of existing lesions on CT scan.
No concomitant systemic therapy for metastatic prostate cancer is allowed except LHRH analogue should be continued if necessary to maintain testosterone suppression.
No concomitant radiation therapy
Prior RT is allowed if completed at least 2 weeks prior to registration.
Presence of measurable or evaluable disease
If RT has been administered, disease outside the RT port is required.
Willingness to sign informed consent.
Registration and willingness to sign informed consent for separate PET protocol 2335 that describes the PET scan procedure.
Patients must have good oral hygiene which includes having a recent dental evaluation
You may not be if
Patients who are unable to swallow
Patients with dental cavities that are likely to need dental extraction or root canal treatment as management
Clareo Health | PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
